Evidence map›Paper›PMID 40614127›Full record

ArticleCancer2025

Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance.

Raeven S Grant, Preeti Kakani, Pranav Movva, Timothy J Daskivich, Steven S Raman, Anthony E Sisk, Wayne G Brisbane, Robert E Reiter, Adam B Weiner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raeven S GrantDepartment of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-9624-4389
Preeti KakaniDepartment of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Pranav MovvaDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0009-0004-4350-1232
Timothy J DaskivichDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-7540-3272
Steven S RamanDepartment of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Anthony E SiskDepartment of Pathology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Wayne G BrisbaneDepartment of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Robert E ReiterDepartment of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Adam B WeinerDepartment of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-1912-042X

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
NCI NIH HHS P50 CA092131NCI NIH HHS T32 CA009213
6 · The paper itself

Abstract

backgroundNearly 12% of patients in the United States with intermediate-risk prostate cancer (PCa) opt for surveillance as their initial management strategy. Patients with aggressive histologic variants, such as cribriform and intraductal carcinoma (IDC), are considered poor candidates for surveillance. The objective of this study was to determine the sensitivity and specificity of magnetic resonance imaging (MRI)-assisted biopsy for detecting cribriform PCa and IDC.

methodsIn this retrospective cohort study, patients who underwent prostate MRI before biopsy within 6 months of prostatectomy at a single institution (2018-2024) were identified. All patients had grade group 2-3 (GG2-3) PCa on biopsy. The primary outcome was the sensitivity of MRI-assisted biopsy for detecting cribriform PCa and IDC by patient in the prostatectomy specimen.

resultsThe authors identified 641 patients who had 1186 tumors that were GG2-3 PCa on biopsy. The median time between MRI and biopsy was 31 days, and the median time between biopsy and surgery was 91 days. Cribriform PCa was identified in 35 patients (5.5%) at the time of biopsy and in 119 patients (18.6%) at surgery. IDC was present in 22 patients (3.4%) at biopsy and in 71 patients (11.1%) at surgery. By patient, the sensitivity for detecting cribriform PCa, IDC, or either was 21.8%, 26.8%, and 29.3%, respectively. The sensitivity by tumor for cribriform PCa, IDC, or either was 20.5%, 27.3%, and 28%, respectively.

conclusionsThe sensitivity of MRI-assisted biopsy for detecting cribriform PCa and IDC in patients with GG2-3 PCa is poor. This work should encourage improvements in detecting variant histologies with optimized biopsy, imaging, and adjunct biomarkers.

Indexed as

Image-Guided BiopsyMagnetic Resonance ImagingProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm GradingProstateProstatectomyRetrospective StudiesSensitivity and SpecificityWatchful Waitingdiagnostic imaginghumansmagnetic resonance imagingprostatic neoplasms

Identifiers

PMID40614127
PMCPMC12272949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.